UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

Molecular Templates, Inc. (Name of Issuer) Common Stock, par value \$0.001 per share (Title of Class of Securities) 608550109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(c) Rule 13d-1(d) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 "Act" or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 608550109 1 NAME OF REPORTING PERSON Biotechnology Value Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) \$\mathred{\text{B}}\$ Biotechnology Value Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (b) \$\mathred{\text{S}}\$ SPIC USE ONLY A CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 5 SOLE VOTING POWER			(Amendment No. 4) ¹	
(Name of Issuer) Common Stock, par value \$0.001 per share (Title of Class of Securities) 608550109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Theck the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(c) Rule 13d-1(d) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would after disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 608550109 1 NAME OF REPORTING PERSON Biotechnology Value Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) \(\begin{align*}(\text{a} \) \\ \(\text{b} \) \(\text{c} \) \(\begin{align*}(\text{a} \) \(\begin{align*}(\text{a} \) \\ \(\text{c} \) \(\text{c} \) \(\text{d} \)				
(Name of Issuer) Common Stock, par value \$0.001 per share (Title of Class of Securities) 608550109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Theck the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(c) Rule 13d-1(d) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would after disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 608550109 1 NAME OF REPORTING PERSON Biotechnology Value Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) \(\begin{align*}(\text{a} \) \\ \(\text{b} \) \(\text{c} \) \(\begin{align*}(\text{a} \) \(\begin{align*}(\text{a} \) \\ \(\text{c} \) \(\text{c} \) \(\text{d} \)				
Common Stock, par value \$0.001 per share (Title of Class of Securities) 608550109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(d) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). ZUSIP No. 608550109 1 NAME OF REPORTING PERSON Biotechnology Value Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ⋈ (b) □ 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 5 SOLE VOTING POWER				
(Title of Class of Securities) 608550109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 608550109 1 NAME OF REPORTING PERSON Biotechnology Value Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) Securities Exchange Act of 1934 CTITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 5 SOLE VOTING POWER			(Name of Issuer)	
(CUSIP Number) Custed Planuber				
CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) Rule 13d-1(d) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). USIP No. 608550109			(Title of Class of Securities)	
December 31, 2021				
(Date of Event Which Requires Filing of this Statement) Theck the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 608550109 1 NAME OF REPORTING PERSON Biotechnology Value Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) Expression of the Act (however, see the Notes) (b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 5 SOLE VOTING POWER			(CUSIP Number)	
(Date of Event Which Requires Filing of this Statement) Theck the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 608550109 1 NAME OF REPORTING PERSON Biotechnology Value Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) Expression of the Act (however, see the Notes) (b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 5 SOLE VOTING POWER			December 31, 2021	
□ Rule 13d-1(b) □ Rule 13d-1(c) □ Rule 13d-1(d) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 608550109 1 NAME OF REPORTING PERSON Biotechnology Value Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☑ (b) □ 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 5 SOLE VOTING POWER				
□ Rule 13d-1(b) □ Rule 13d-1(c) □ Rule 13d-1(d) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 608550109 1 NAME OF REPORTING PERSON Biotechnology Value Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☑ (b) □ 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 5 SOLE VOTING POWER				
□ Rule 13d-1(b) □ Rule 13d-1(c) □ Rule 13d-1(d) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 608550109 1 NAME OF REPORTING PERSON Biotechnology Value Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☑ (b) □ 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 5 SOLE VOTING POWER				
Rule 13d-1(c) Rule 13d-1(d) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 608550109 1 NAME OF REPORTING PERSON Biotechnology Value Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b) (b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 5 SOLE VOTING POWER	Check the appropriate box	to designate the rule pursu	ant to which this Schedule is filed:	
Rule 13d-1(c) Rule 13d-1(d) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 608550109 1 NAME OF REPORTING PERSON Biotechnology Value Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b) (b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 5 SOLE VOTING POWER	☐ Rule 13d-1(b)		
The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). [USIP No. 608550109] 1	_	,		
The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 608550109 1 NAME OF REPORTING PERSON Biotechnology Value Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 5 SOLE VOTING POWER	⊠ Rule 13d-1(c)		
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 608550109 1 NAME OF REPORTING PERSON Biotechnology Value Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 5 SOLE VOTING POWER	☐ Rule 13d-1(d)		
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 608550109 1 NAME OF REPORTING PERSON Biotechnology Value Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 5 SOLE VOTING POWER				
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 608550109 1 NAME OF REPORTING PERSON Biotechnology Value Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 5 SOLE VOTING POWER				
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 608550109 1 NAME OF REPORTING PERSON Biotechnology Value Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 5 SOLE VOTING POWER				
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 608550109 1 NAME OF REPORTING PERSON Biotechnology Value Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 5 SOLE VOTING POWER				
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 1	1 The remainder of	this cover page shall be fi	lled out for a reporting person's initial filing on this form with respect to the subject would alter disclosures provided in a prior cover page.	ct class of securities, and for any
"Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 608550109 1 NAME OF REPORTING PERSON Biotechnology Value Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b) (b) (c) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 5 SOLE VOTING POWER	-	-	• • • •	
CUSIP No. 608550109 1 NAME OF REPORTING PERSON Biotechnology Value Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ⊠ (b) □ 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 5 SOLE VOTING POWER	The information r	equired on the remainder	of this cover page shall not be deemed to be "filed" for the purpose of Section 18 c	f the Securities Exchange Act of 1934
1 NAME OF REPORTING PERSON Biotechnology Value Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ⊠ (b) □ 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 5 SOLE VOTING POWER	("Act") or otherwise subject	et to the liabilities of that s	ection of the Act but shall be subject to all other provisions of the Act (however, s	ee the Notes).
1 NAME OF REPORTING PERSON Biotechnology Value Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ⊠ (b) □ 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 5 SOLE VOTING POWER				
1 NAME OF REPORTING PERSON Biotechnology Value Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ⊠ (b) □ 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 5 SOLE VOTING POWER	CUSIP No. 608550109			
Biotechnology Value Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 5 SOLE VOTING POWER	20011 1101 000000107			
Biotechnology Value Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 5 SOLE VOTING POWER	1	NAME OF REPORTIN	JG PERSON	
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 5 SOLE VOTING POWER		I WHILL OF REPORTE	TO I ENDOIN	
3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 5 SOLE VOTING POWER				
3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 5 SOLE VOTING POWER	2	CHECK THE APPRO	PRIATE BOX IF A MEMBER OF A GROUP	
4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 5 SOLE VOTING POWER				(6) □
Delaware NUMBER OF 5 SOLE VOTING POWER	3	SEC USE ONLY		
Delaware NUMBER OF 5 SOLE VOTING POWER				
Delaware NUMBER OF 5 SOLE VOTING POWER		CITIZENSHID OD DI	ACE OF OPGANIZATION	
NUMBER OF 5 SOLE VOTING POWER	,	CITIZENSIIII OR FL	ACE OF ORGANIZATION	
CHADLE		5	SOLE VOTING POWER	
SHARES BENEFICIALLY 0 shares			0 shares	<u>!</u>

SHARED VOTING POWER

1,746,256 (1)

1,746,256 (1) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

SOLE DISPOSITIVE POWER

SHARED DISPOSITIVE POWER

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

OWNED BY

EACH REPORTING

PERSON WITH

9

10

11

6

7

8

1,746,256 (1)

3.1% (1)

12	TYPE OF REPORTING PERSON
	PN

(1) Includes 128,000 shares of Common Stock (defined in Item 4) currently issuable upon the conversion of certain Series A Convertible Preferred (defined in Item 4).

2

CUSIP No. 608550109

1	NAME OF REPORT	TING PERSON		
	BVF I GP LLC			
2		OPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵	
			(b) 🗆	
3	SEC USE ONLY			
4	CITIZENSHIP OR I	PLACE OF ORGANIZATION		
	Delaware			
NUMBER OF	5	SOLE VOTING POWER		
SHARES BENEFICIALLY		0 shares		
OWNED BY	6	SHARED VOTING POWER		
EACH REPORTING		1,746,256 (1)		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
		0 shares		
	8	SHARED DISPOSITIVE POWER		
		1,746,256 (1)		
9	AGGREGATE AMO	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	1,746,256 (1)			
10	CHECK BOX IF TH	IE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)		
	3.1%(1)			
12	TYPE OF REPORT	ING PERSON		
	00			

(1) Includes 128,000 shares of Common Stock currently issuable upon the conversion of certain Series A Convertible Preferred.

3

1	NAME OF REPOR	NAME OF REPORTING PERSON		
	D' 4 1 1	VI P III I		
2		gy Value Fund II, L.P. ROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵	
2	CHECK THE APP	ROPKIATE BOATF A MEMBER OF A GROUP	(a) ⊠ (b) □	
			(6) 🗆	
3	SEC USE ONLY			
4	CITIZENSHIP OR	PLACE OF ORGANIZATION		
	Delaware			
NUMBER OF	5	SOLE VOTING POWER		
SHARES				
BENEFICIALLY		0 shares		
OWNED BY	6	SHARED VOTING POWER		
EACH REPORTING		1,378,809 (1)		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
	,	SOLL BISTOSITI VETO WELL		
		0 shares		
	8	SHARED DISPOSITIVE POWER		
		1,378,809 (1)		
9	AGGREGATE AM	IOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	1,378,809 (1)		
10		HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	П	
10	CHECK BOATH 1	III II OOLO OO II II II OO II (), BIODODES CERTIII SIII II EE		

11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	2.4% (1)
12	TYPE OF REPORTING PERSON
	PN

(1) Includes 104,000 shares of Common Stock currently issuable upon the conversion of certain Series A Convertible Preferred.

4

CUSIP No. 608550109

1	NAME OF REPOR	TING PERSON			
		NUMBER OF THE STATE OF THE STAT			
	BVF II GP L				
2	CHECK THE APPR	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵		
			(b) 🗆		
	and tion of it.				
3	SEC USE ONLY		:		
			-		
4	CITIZENCHID OD	PLACE OF ORGANIZATION			
'	CITIZENSHIF OK	FLACE OF ORGANIZATION			
	Delaware				
NUMBER OF	5	SOLE VOTING POWER			
SHARES					
BENEFICIALLY		0 shares			
OWNED BY	6	SHARED VOTING POWER			
EACH					
REPORTING		1,378,809 (1)			
PERSON WITH	7	SOLE DISPOSITIVE POWER			
		0.1	:		
	8	0 shares SHARED DISPOSITIVE POWER			
	8	SHARED DISPOSITIVE POWER			
		1,378,809 (1)			
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
		· · · · · · · · · · · · · · · · · · ·			
Ĭ	1,378,809 (1)				
10	CHECK BOX IF TH	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES			
11	PERCENT OF CLA	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)			
	2.40/ (1)				
12	2.4% (1) TYPE OF REPORT	TAIC DED CON			
12	1 1 PE OF KEPORT	INO FERSON			
	00				

(1) Includes 104,000 shares of Common Stock currently issuable upon the conversion of certain Series A Convertible Preferred.

5

1 NAME OF REPORTING PERSON Biotechnology Value Trading Fund OS LP 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ⊠ (b) □ 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE DISPOSITIVE POWER 191,242 (1) 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ⊠ (b) □ 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE DISPOSITIVE POWER 9 shares 8 SHARED DISPOSITIVE POWER 191,242 (1)	1	NAME OF REPORT	ING PERSON		
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ⊠ (b) □ 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE DISPOSITIVE POWER 9 shares 8 SHARED DISPOSITIVE POWER 191,242 (1)					
3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING 191,242 (1) PERSON WITH 7 SOLE DISPOSITIVE POWER 8 SHARED DISPOSITIVE POWER 191,242 (1)		Biotechnology	Value Trading Fund OS LP		
3 SEC USE ONLY	2	CHECK THE APPRO	OPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵	
4 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE DISPOSITIVE POWER 8 SHARED DISPOSITIVE POWER 191,242 (1)				(b) 🗆	
4 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE DISPOSITIVE POWER 8 SHARED DISPOSITIVE POWER 191,242 (1)					
Cayman Islands	3	SEC USE ONLY			
Cayman Islands					
Cayman Islands					
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER 5 SOLE VOTING POWER 6 SHARED VOTING POWER 191,242 (1) 7 SOLE DISPOSITIVE POWER 0 shares 8 SHARED DISPOSITIVE POWER 191,242 (1)	4	CITIZENSHIP OR P	LACE OF ORGANIZATION		
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER 5 SOLE VOTING POWER 0 shares 191,242 (1) 7 SOLE DISPOSITIVE POWER 0 shares 8 SHARED DISPOSITIVE POWER 191,242 (1)					
SHARES		_			
BENEFICIALLY		5	SOLE VOTING POWER		
OWNED BY EACH REPORTING PERSON WITH 7 SOLE DISPOSITIVE POWER 0 shares 8 SHARED DISPOSITIVE POWER 191,242 (1)					
EACH REPORTING 191,242 (1) PERSON WITH 7 SOLE DISPOSITIVE POWER 0 shares 8 SHARED DISPOSITIVE POWER 191,242 (1)	1		1 2 1 12		
REPORTING 191,242 (1) PERSON WITH 7 SOLE DISPOSITIVE POWER 0 shares 8 SHARED DISPOSITIVE POWER 191,242 (1) 191,242 (1)	1	6	SHARED VOTING POWER		
PERSON WITH 7 SOLE DISPOSITIVE POWER 0 shares 8 SHARED DISPOSITIVE POWER 191,242 (1)			101.010 (1)		
0 shares 8 SHARED DISPOSITIVE POWER 191,242 (1)	REPORTING		191,242 (1)		
0 shares 8 SHARED DISPOSITIVE POWER 191,242 (1)	PERSON WITH	7	SOLE DISPOSITIVE POWER		
8 SHARED DISPOSITIVE POWER 191,242 (1)	TERSOIT WITH	,	SOLE DISTOSITIVE TO WER		
8 SHARED DISPOSITIVE POWER 191,242 (1)			0 shares		
191,242 (1)		8	* ********		
			STATES STOT SOUTH BY STATES		
			191,242 (1)		
	9	AGGREGATE AMO		•	
\mathbf{i}					

	191,242 (1)	
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	
	Less than 1% (1)	
12	TYPE OF REPORTING PERSON	
]		
	PN	

(1) Includes 18,000 shares of Common Stock currently issuable upon the conversion of certain Series A Convertible Preferred.

6

CUSIP No. 608550109

	1		
1	NAME OF REPOR	TING PERSON	
	BVF Partners		
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ⊠		
			(b) 🗆
3	SEC USE ONLY		
4	CITIZENSHID OD	PLACE OF ORGANIZATION	
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
i	Cayman Islan	nds	
NUMBER OF	5	SOLE VOTING POWER	
SHARES		SOLE VOTINGTOWER	
BENEFICIALLY		0 shares	
OWNED BY	6	SHARED VOTING POWER	
EACH			
REPORTING		191,242 (1)	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0 shares	
-	8	SHARED DISPOSITIVE POWER	
		191,242 (1)	
9	AGGDEGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
1	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING LERSON	
	191,242 (1)		
10		HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
Ĭ			
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
<u> </u>			
	Less than 1%		
12	TYPE OF REPORT	ING PERSON	
	CO		
	CO		

 $(1) \ Includes \ 18,\!000 \ shares \ of \ Common \ Stock \ currently \ is suable \ upon \ the \ conversion \ of \ certain \ Series \ A \ Convertible \ Preferred.$

7

1	NAME OF REPOR	TING PERSON	
	BVF GP Hol	dings LLC	
2	CHECK THE APPI	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF	5	SOLE VOTING POWER	
SHARES BENEFICIALLY		0 shares	
OWNED BY	6	SHARED VOTING POWER	
EACH		2 125 065 (1)	
REPORTING PERSON WITH	7	3,125,065 (1) SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	

		ļ
	3,125,065 (1)	j
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
		I
	3,125,065 (1)	
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	
	5.5% (1)	
12	TYPE OF REPORTING PERSON	
	00	-

(1) Includes 232,000 shares of Common Stock currently issuable upon the conversion of certain Series A Convertible Preferred.

8

CUSIP No. 608550109

1	NAME OF REPOR	RTING PERSON			
	D				
2	BVF Partner	rs L.P. ROPRIATE BOX IF A MEMBER OF A GROUP	() [7]		
2	CHECK THE APP	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □		
			(0) 🗆		
3	SEC USE ONLY	SEC USE ONLY			
4	CITIZENSHIP OR	PLACE OF ORGANIZATION			
	Delaware				
NUMBER OF	5	SOLE VOTING POWER			
SHARES					
BENEFICIALLY OWNED BY		0 shares			
EACH	6	SHARED VOTING POWER			
REPORTING		3,379,599 (1)			
PERSON WITH	7	SOLE DISPOSITIVE POWER			
	0	0 shares			
 	8	SHARED DISPOSITIVE POWER			
		3,379,599 (1)			
9	AGGREGATE AM	IOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2				
10	3,379,599 (1				
10	CHECK BOX IF I	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	Ц		
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)			
	(00/ (1)				
12	6.0% (1) TYPE OF REPORT	TING DED SON			
12	11PE OF KEPOK	TING FERSON			
	PN, IA				

(1) Includes 250,000 shares of Common Stock currently issuable upon the conversion of certain Series A Convertible Preferred.

9

1	NAME OF REPORTING PERSON		
	BVF Inc.		
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) \boxtimes (b) \Box		
3	SEC USE ONLY		
4	CITIZENSHIP OR PLACE OF ORGANIZATION		
	Delaware		
NUMBER OF	5	SOLE VOTING POWER	
SHARES BENEFICIALLY		0 shares	
OWNED BY	6	SHARED VOTING POWER	
EACH REPORTING		3,379,599 (1)	

PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		3,379,599 (1)	
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	3,379,599 (1)		
10	CHECK BOX IF THI	E AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)		
	6.0% (1)		
12	TYPE OF REPORTIN	NG PERSON	
	CO		

(1) Includes 250,000 shares of Common Stock currently issuable upon the conversion of certain Series A Convertible Preferred.

10

CUSIP No. 608550109

1	NAME OF REPORTING PERSON				
	Mark N. Lan				
2	CHECK THE APPI	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠		
			(b) □		
3	SEC USE ONLY				
]	SEC USE ONL!				
4 CITIZENSHIP OR PLACE OF ORGANIZATION		PLACE OF ORGANIZATION			
	United States				
NUMBER OF	5	SOLE VOTING POWER			
SHARES BENEFICIALLY		0 shares			
OWNED BY	6	SHARED VOTING POWER			
EACH		SHINED VOINGTOWER			
REPORTING		3,379,599 (1)			
PERSON WITH	7	SOLE DISPOSITIVE POWER			
		0 shares			
	8	SHARED DISPOSITIVE POWER			
		3,379,599 (1)			
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	110011201121111				
	3,379,599 (1				
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES				
11	DED CENT OF CLA	OG DEDDEGENTED DV AMOUNTE DI DOM (A)			
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
	6.0% (1)				
12	TYPE OF REPORTING PERSON				
1.2	I I I I I I I I I I I I I I I I I I I				
	IN				

(1) Includes 250,000 shares of Common Stock currently issuable upon the conversion of certain Series A Convertible Preferred.

11

CUSIP No. 608550109

Item 1(a). Name of Issuer:

Molecular Templates, Inc., a Delaware corporation (the "Issuer").

Item 1(b). Address of Issuer's Principal Executive Offices:

9301 Amberglen Blvd., Suite 100

Austin, Texas 78729

Item 2(a). Name of Person Filing

Item 2(b). Address of Principal Business Office or, if None, Residence

Item 2(c). Citizenship

Biotechnology Value Fund, L.P. ("BVF") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

BVF I GP LLC ("BVF GP") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

Biotechnology Value Fund II, L.P. ("BVF2") 44 Montgomery St., 40th Floor

Citizenship: Delaware

BVF II GP LLC ("BVF2 GP") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

San Francisco, California 94104

Biotechnology Value Trading Fund OS LP ("Trading Fund OS") PO Box 309 Ugland House Grand Cayman, KY1-1104

Cayman Islands

Citizenship: Cayman Islands

BVF Partners OS Ltd. ("Partners OS") PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands Citizenship: Cayman Islands

BVF GP Holdings LLC ("BVF GPH") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

12

CUSIP No. 608550109

BVF Partners L.P. ("Partners") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

BVF Inc.

44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

Mark N. Lampert ("Mr. Lampert") 44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: United States

Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."

Item 2(d). Title of Class of Securities:

Common stock, \$0.001 par value per share (the "Common Stock")

Item 2(e). CUSIP Number:

608550109

Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

	/x/	Not applicable.	
(a)	//	Broker or dealer registered under Section 15 of the Exchange Act.	
(b)	//	Bank as defined in Section 3(a)(6) of the Exchange Act.	
(c)	//	Insurance company as defined in Section 3(a)(19) of the Exchange Act.	
(d)	//	Investment company registered under Section 8 of the Investment Company Act.	
(e)	//	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).	
(f)	//	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).	
(g)	//	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).	
(h)	//	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.	
(i)	//	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.	

- (j) // Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
- (k) // Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii) (J), please specify the type of institution: ____

13

CUSIP No. 608550109

Item 4. Ownership

(a) Amount beneficially owned:

As of the close of business on December 31, 2021, the Reporting Persons held 250 shares of Series A Convertible Preferred Stock (the "Series A Convertible Preferred") convertible for an aggregate of 250,000 shares of Common Stock. The Series A Convertible Preferred may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934 (the "Exchange Act"), more than 9.99% of the number of shares of Common Stock then issued and outstanding (the "Series A Blocker"). As of the close of business on December 31, 2021, the Series A Blocker does not limit the conversion of any of the Series A Convertible Preferred owned by the Reporting Persons.

As of the close of business on December 31, 2021, the Reporting Persons held 362,064 warrants, exercisable for an aggregate of 362,064 shares of Common Stock (the "Warrants"). The Warrants have an exercise price of \$6.8423 per share and expire on August 1, 2024. The Warrants are only exercisable to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would not beneficially own more than 4.99% of the outstanding shares of Common Stock after giving effect to such exercise, as such percentage ownership is determined in accordance with the terms of the Warrants (the "Beneficial Ownership Limitation"). As of December 31, 2021, the Beneficial Ownership Limitation limits the aggregate exercise of the Warrants by the Reporting Persons to 0 out of the 362,064 shares of Common Stock underlying the Warrants owned by the Reporting Persons in the aggregate. BVF holds Warrants to purchase 168,508 shares of Common Stock which are excluded herein as a result of the Beneficial Ownership Limitation. BVF2 holds Warrants to purchase 30,190 shares of Common Stock which are excluded herein as a result of the Beneficial Ownership Limitation. Certain accounts managed by Partners (the "Partners Managed Accounts") hold Warrants to purchase 54,830 shares of Common Stock which are excluded herein as a result of the Beneficial Ownership Limitation.

As of the close of business on December 31, 2021, (i) BVF beneficially owned 1,746,256 shares of Common Stock, including 128,000 shares of Common Stock issuable upon the conversion of certain Series A Convertible Preferred, (ii) BVF2 beneficially owned 1,378,809 shares of Common Stock, including 104,000 shares of Common Stock issuable upon the conversion of certain Series A Convertible Preferred, and (iii) Trading Fund OS beneficially owned 191,242 shares of Common Stock, including 18,000 shares of Common Stock issuable upon the conversion of certain Series A Convertible Preferred.

14

CUSIP No. 608550109

BVF GP, as the general partner of BVF, may be deemed to beneficially own the 1,746,256 shares of Common Stock beneficially owned by BVF.

BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 1,378,809 shares of Common Stock beneficially owned by BVF2.

Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 191,242 shares of Common Stock beneficially owned by Trading Fund OS.

BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 3,125,065 shares of Common Stock beneficially owned in the aggregate by BVF and BVF2.

Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 3,379,599 shares of Common Stock beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Accounts, including 63,292 shares of Common Stock held in the Partners Managed Accounts.

BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 3,379,599 shares of Common Stock beneficially owned by Partners.

Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 3,379,599 shares of Common Stock beneficially owned by BVF Inc.

The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any shares of Common Stock owned by another Reporting Person. BVF GP disclaims beneficial ownership of the shares of Common Stock beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the shares of Common Stock beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the shares of Common Stock beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the shares of Common Stock beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the shares of Common Stock beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Accounts, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

(b) Percent of class:

The following percentages are based on a denominator that is the sum of (i) 56,305,049 shares of Common Stock outstanding as of November 8, 2021, as disclosed by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 15, 2021, and (ii) certain or all of the 250,000 shares of Common Stock issuable upon the conversion of the Series A Convertible Preferred, as applicable.

As of the close of business on December 31, 2021, (i) BVF beneficially owned approximately 3.1% of the outstanding shares of Common Stock, (ii) BVF2 beneficially owned approximately 2.4% of the outstanding shares of Common Stock, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding shares of Common Stock, (iv) BVF GP may be deemed to beneficially own approximately 3.1% of the outstanding shares of Common Stock, (v) BVF2 GP may be deemed to beneficially own approximately 2.4% of the outstanding shares of Common Stock, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding shares of Common Stock, (vii) BVF GPH may be deemed to beneficially own approximately 5.5% of the outstanding shares of Common Stock and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 6.0% of the outstanding shares of Common Stock (less than 1% of the outstanding shares of Common Stock is held in the Partners Managed Accounts).

CUSIP No. 608550109

- (c) Number of shares as to which such person has:
- (i) Sole power to vote or to direct the vote

See Cover Pages Items 5-9.

(ii) Shared power to vote or to direct the vote

See Cover Pages Items 5-9.

(iii) Sole power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

(iv) Shared power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

Item 5. Ownership of Five Percent or Less of a Class.

Not Applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the shares of Common Stock beneficially owned by BVF and BVF2. Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the shares of Common Stock beneficially owned by Trading Fund OS and held in the Partners Managed Accounts.

the furthers managed recounts.

Item 7. Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

See Exhibit 99.1 to Amendment No. 2 to the Schedule 13G filed with the Securities and Exchange Commission on February 14, 2020.

Item 9. Notice of Dissolution of Group.

Not Applicable.

16

CUSIP No. 608550109

Item 10. Certifications.

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

17

CUSIP No. 608550109

SIGNATURE

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2022

BIOTECHNOLOGY VALUE FUND, L.P.

By: BVF I GP LLC., its general partner

By: /s/ Mark N. Lampert Mark N. Lampert Chief Executive Officer

BVF I GP LLC

By: /s/ Mark N. Lampert

Mark N. Lampert Chief Executive Officer BIOTECHNOLOGY VALUE TRADING FUND OS LP

By: BVF Partners L.P., its investment manager

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert
Mark N. Lampert
President

BVF GP HOLDINGS LLC

By: /s/ Mark N. Lampert

Mark N. Lampert

Chief Executive Officer

BIOTECHNOLOGY VALUE FUND II, L.P.

By: BVF II GP LLC, its general partner

By: /s/ Mark N. Lampert Mark N. Lampert BVF PARTNERS L.P.

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Chief Executive Officer Mark N. Lampert President BVF II GP LLC BVF INC. /s/ Mark N. Lampert Mark N. Lampert By: /s/ Mark N. Lampert Mark N. Lampert Chief Executive Officer President BVF PARTNERS OS LTD. /s/ Mark N. Lampert By: BVF Partners L.P., its sole member MARK N. LAMPERT BVF Inc., its general partner By:

18

/s/ Mark N. Lampert Mark N. Lampert

President

By: